Association between copeptin levels and treatment responses to hypertonic saline infusion in patients with symptomatic hyponatremia: a prospective cohort study
Open Access
- 30 September 2021
- journal article
- research article
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 40 (3) , 371-382
Abstract
Background: Copeptin is secreted in equimolar amounts as arginine vasopressin, main hormone regulating body fluid homeostasis. A recent study reported a copeptin-based classification of osmoregulatory defects in syndromes of inappropriate antidiuresis that may aid in prediction of therapeutic success. We investigated usefulness of copeptin for differentiating etiologies of hyponatremia and predicting efficacy and safety of hypertonic saline treatment in hyponatremic patients. Methods: We performed a multicenter, prospective cohort study of 100 inpatients with symptomatic hyponatremia (corrected serum sodium [sNa] <= 125 mmol/L) treated with hypertonic saline. Copeptin levels were measured at baseline and 24 hours after treatment initiation, and patients were classified as being below or above median of copeptin at baseline or at 24 hours, respectively. Correlations between target, under correction, and overcorrection rates of sNa within 24 hours/24-48 hours and copeptin levels at baseline/24 hours were analyzed. Results: Mean sNa and median copeptin levels were 117.9 and 16.9 pmol/L, respectively. Ratio of copeptin-to-urine sodium allowed for an improved differentiation among some (insufficient effective circulatory volume), but not all hyponatremia etiologic subgroups. Patients with below-median copeptin levels at baseline achieved a higher target correction rate in 6/24 hours (odds ratio [OR], 2.97; p = 0.02/OR, 6.21; p = 0.006). Patients with below-median copeptin levels 24 hours after treatment showed a higher overcorrection rate in next 24 hours (OR, 18.00, p = 0.02). Conclusion: There is a limited diagnostic utility of copeptin for differential diagnosis of hyponatremia. However, copeptin might be useful for predicting responses to hypertonic saline treatment in hyponatremic patients.Keywords
Funding Information
- Hallym University (HURF-2018-29)
- Korean Association of Internal Medicine (2018-180)
- National Research Foundation of Korea (2016R1C1B1015687)
This publication has 44 references indexed in Scilit:
- Plasma copeptin, a possible prognostic marker in cirrhosisLiver International, 2013
- Combined Testing of High-Sensitivity Troponin T and Copeptin on Presentation at Prespecified Cutoffs Improves Rapid Rule-Out of Non–ST-Segment Elevation Myocardial InfarctionClinical Chemistry, 2011
- Mortality and Serum SodiumClinical Journal of the American Society of Nephrology, 2011
- Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome – revisiting the direct and indirect water deprivation testsExperimental and Clinical Endocrinology & Diabetes, 2010
- Copeptin in the differential diagnosis of hyponatremiaExperimental and Clinical Endocrinology & Diabetes, 2008
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006
- HyponatremiaNew England Journal of Medicine, 2000
- Plasma ANP during hypertonic NaCl infusion in manActa Physiologica Scandinavica, 1992
- Osmotic Demyelination Syndrome Following Correction of HyponatremiaNew England Journal of Medicine, 1986